Sign inHS 300490
| Year | Direction | Value | Quantity | Net weight | How it was measured |
|---|---|---|---|---|---|
| 2024 | Imports | $894.6M | 8,532,633 kg | 8,532 t | Aggregated by UNSD · weight estimated |
| 2024 | Exports | $17.6B | 594,357,542 kg | 594,357 t | Aggregated by UNSD · weight estimated |
| 2023 | Exports | $16B | 552,415,641 kg | 552,415 t | Aggregated by UNSD · weight estimated |
| 2023 | Imports | $870.2M | 7,691,072 kg | 7,691 t | Aggregated by UNSD · weight estimated |
| 2022 | Imports | $797.2M | 9,579,555 kg | 9,579 t | Aggregated by UNSD · weight estimated |
| 2022 | Exports | $14.8B | 488,965,224 kg | 488,965 t | Aggregated by UNSD · weight estimated |
| 2021 | Exports | $14.7B | 410,516,971 kg | 410,516 t | Aggregated by UNSD · weight estimated |
| 2021 | Imports | $1.3B | 9,349,317 kg | 9,349 t | Aggregated by UNSD · weight estimated |
| 2020 | Exports | $14B | 226,444,489 kg | 226,444 t | Aggregated by UNSD · weight estimated |
| 2020 | Imports | $732.4M | 6,783,430 kg | 6,783 t | Aggregated by UNSD · weight estimated |
| 2019 | Exports | $12.3B | 189,636,323 kg | 189,636 t | Aggregated by UNSD · weight estimated |
| 2019 | Imports | $955.1M | 14,688,291 kg | 14,688 t | Aggregated by UNSD · weight estimated |
Source: UN Comtrade · https://comtradeapi.un.org. Figures are for all trading partners combined.
Nobody has published a domestic substitute for this commodity yet. Substitutes are curated, so an empty list means nothing has been recorded — not that no substitute exists.
Written by a language model over the score above. Advisory — it decides nothing and moves no figure.
This pathway outlines the steps to establish domestic manufacturing for medicaments in India, a market with significant annual imports of USD 894,669,237, substantial export capability, but currently recorded zero domestic substitutes or suppliers with a matching capability. Conduct Regulatory and Compliance Mapping: Begin by engaging with national drug regulatory authorities to map out the required manufacturing licenses, GMP certifications, and product registrations for retail-packaged therapeutics. Facility Planning and Equipment Sourcing: Design a compliant cleanroom and formulation facility, unblocking the procurement of specialized mixing, granulation, and retail packaging machinery. Supply Chain and Raw Material Validation: Identify and qualify active pharmaceutical ingredient (API) and excipient suppliers to secure consistent input streams, mitigating the risk of relying on import-dependent supply chains. Pilot Batch Production and Testing: Execute trial runs and stability testing on the first commercial line to validate product efficacy and meet regulatory quality standards. Risks: Zero recorded domestic suppliers with a matching capability, leading to potential bottlenecks in local specialized labor and equipment maintenance. High import dependence score of 26/35, reflecting vulnerability in raw material or API supply chains. Stringent regulatory compliance requirements and lengthy approval timelines for pharmaceutical manufacturing. Significant capital expenditure requirements with uncertain return timelines.
gemini-3.5-flash-lite (gemini-3.5-flash-lite) · prompt localization-narrative-v3 · 65% confidence